Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

785 - Is Fotemustine a good option after irinotecan-bevacizumab in high-grade glioma? (128P)

Date

18 Nov 2017

Session

Poster lunch

Topics

Cytotoxic Therapy;  Central Nervous System Malignancies

Presenters

Patricia Ramirez Daffós

Citation

Annals of Oncology (2017) 28 (suppl_10): x35-x38. 10.1093/annonc/mdx657

Authors

P. Ramirez Daffós, M.J. Martinez Bautista, G. Blanco Sanchez(, S. Estalella, J.M. Baena Cañada

Author affiliations

  • Medical Oncology, Puerta del Mar, 11006 - cadiz/ES
More

Resources

Abstract 785

Background

Recurrent high-grade glioma (GAG), don't usually benefit from a second surgery or reirradiation. With the addition of bevacizumab or fotemustine (FTM), the median OS is 9.2 and 8 months, respectively. There is no currently clinical trial showing a 3rd line treatment benefit in recurrent GAG. The aim of this study is to describe the clinical experience in our hospital with FTM in 3rd line.

Methods

An observational, retrospective study was conducted. All patients had progressed to temozolomide and irinotecan+bevacizumab and had received at least one cycle of fotemustine (FTM) from 2010 to the present. The schedule was: induction doses with 80 mg/m2 intravenously on days 1–15–30–45–60 and maintenance with 80 mg/m2 every 3 weeks.

Results

7 patients were included, 5 women, median age 41 years, 42% (n = 3) were anaplastic astrocytomas and 58% (n = 4) multiform glioblastoma, 100% of the patients had PS 0–1. To date, 6 of the 7 patients had progressed, with a median PFS of 1 month. The 3- month survival rate was 71.42%, and the median OS (5/7 deceased patients) was 3.3 months. No adverse events of grade ≥3 were reported.

Conclusions

Fotemustine in third line treatment of GAG shows moderate effectiveness but is a well tolerated treatment, so it could be considered in the third line in patients with GAG with good functional status.

Legal entity responsible for the study

Patricia Ramirez

Funding: None

Disclosure: All authors have declared no conflicts of interest.

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.